OR WAIT null SECS
May 17, 2024
TekniPlex recently acquired Seisa Medical, which has expanded the company's services into that of a CDMO.
The new 80,000-square-foot facility will increase production of the company’s freeze-drying equipment.
May 07, 2024
ProPharm and PBL have introduced a fully automated, enclosed cell factory manufacturing device.
April 27, 2024
SK pharmteco, a CDMO, will manufacture, test, and release Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy from Ferring Pharmaceuticals for treating bladder cancer.
April 24, 2024
In a new agreement, Cellares will utilize its Cell Shuttle fully automated cell therapy manufacturing platform to manufacture select CAR-T cell therapies under development by Bristol Myers Squibb.
April 11, 2024
Charles River has entered into separate agreements with Axovia Therapeutics and Ship of Theseus to offer plasmid DNA manufacturing services for a gene therapy and a lead candidate program, respectively.
April 05, 2024
Under a collaboration agreement, Lonza will manufacture sabirnetug, Acumen Pharmaceuticals' mAb in clinical development for treating Alzheimer’s disease.
April 04, 2024
Genmab's acquisition of ProfoundBio will boost its clinical and preclinical pipeline of ADCs for targeted cancer treatment.
March 29, 2024
Dr. Reddy’s has gained exclusive rights to promote and distribute Sanofi’s vaccines in India.
March 26, 2024
The Vacaville, Calif., site acquisition gives Lonza one of the largest biologics manufacturing sites for mammalian cell-based therapies worldwide.